Moderna Lowers 2025 Revenue Forecast but Beats Q3 Expectations
Moderna cut its 2025 revenue forecast due to weak U.S. COVID-19 vaccine sales but beat Wall Street’s Q3 estimates, lifting shares premarket.
/ 20 items
#GSK↓
GSK Raises 2025 Profit Forecast as HIV and Cancer Drugs Drive Growth
GSK boosts annual profit forecast to 12% growth as specialty medicines outperform. CEO Emma Walmsley's final report shows strong Q3 results despite US vaccine challenges.
Alector Cuts Half Its Workforce After Failed Dementia Drug Trial
Alector announces 49% workforce reduction and discontinuation of latozinemab trials after Phase 3 study fails to show clinical benefit in frontotemporal dementia patients.
Shah Capital Urges Novavax Sale After COVID Vaccine Struggles Continue
Novavax's second-largest shareholder Shah Capital pushes for company sale, citing poor COVID vaccine sales and untapped potential worth $5 billion under larger pharma ownership.
European Drugmakers Surge: Pfizer's US Pricing Deal Offers a Tariff Blueprint
Pfizer avoided US tariffs by offering big drug discounts (TrumpRx). This deal is a blueprint. European drug stocks (AstraZeneca, Roche) surged hoping for similar agreements to protect their crucial sales from Trump's 100% import tax threat.
Pfizer Leads the Way on Drug Pricing and Domestic Investment
Pfizer becomes the first pharmaceutical company to announce a drug-pricing deal with the Trump administration, promising lower prices for up to 100 million patients and committing $70 billion to domestic R&D and manufacturing.